ArticleApplied microbiology and biotechnology2026
S-equol producing bacteria: isolation and identification from Albino Wistar rat gut microbiota.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The metabolism of soy isoflavones by gut microbiota is critical for the bioactivation and bioavailability of these compounds, particularly daidzein, which is further metabolized by gut bacteria to produce S-equol. S-equol, an exclusive gut bacterial metabolite, is associated with health benefits such as reduced blood pressure, cardiovascular disease prevention, and protection against hormone-related cancers due to its estrogen-mimicking structure and antioxidant properties. However, the limited availability of S-equol-producing bacteria has hindered its production and utilization. This study investigates the isolation and characterization of S-equol-producing microbes from albino Wistar rats and explores the impact of dietary interventions on S-equol production. Preliminary tests showed that both dietary groups excreted more S-equol in feces than urine, with rats on fermented soy feed showing higher S-equol levels due to the presence of daidzein, a precursor. In this study, we isolated four anaerobic S-equol-producing bacteria - MG1 (PX459562), MG2 (PX459563), MG3 (PX459564), and MG4 (PX459565) from the intestine and feces of albino Wistar rats. High-Performance Thin-Layer Chromatography (HPTLC) and High-Performance Liquid Chromatography (HPLC) confirmed the presence of S-equol, with concentrations ranging from 5.90 to 7.56 µg/g of fermented soybean across different strains. Phylogenetic analysis revealed that the isolates belonged to the Enterobacteriaceae and Enterococcaceae families, identifying MG1 as C. freundii strain ATCC 8090, MG2 as Escherichia fergusonii strain NBRC 102419, and both MG3 and MG4 as Enterococcus faecalis strain NBRC 100480. Our findings underscore the significant role of gut microbiota in metabolizing daidzein into S-equol, highlighting the potential for utilizing these bacterial strains in functional food development and therapeutic applications. While the pathogenic nature of E. fergusonii (MG2) precludes its therapeutic use, strains MG1, MG3, and MG4, which match common commensal bacteria, show promise for commercial S-equol production and may serve as valuable resources for further investigation and utilization in promoting health and preventing associated diseases. KEY POINTS: • Dietary intervention modulates gut microbiota in albino Wistar rats. • Soybean fermentation enables efficient conversion of daidzin to bioactive S-equol. • Novel S-equol-producing microbes were isolated and identified.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.